Massachusetts eHealth Collaborative

maehc.org

The Massachusetts eHealth Collaborative (MAeHC) is a pioneer and national leader in health information technology. We assist for-profit and non-profit private organizations, government agencies, and multi-stakeholder collaborative to plan, deploy, operate, and optimize health information systems. Our services range from electronic health records (EHR) implementations to health information exchange (HIE) to quality data extraction, warehousing, analytics, and reporting.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

ICHNOS SCIENCES ENTERS LICENSING AGREEMENT FOR OX40 ANTAGONIST MONOCLONAL ANTIBODY PORTFOLIO WITH ASTRIA THERAPEUTICS

PR Newswire | October 12, 2023

news image

Ichnos Sciences, a global clinical-stage biotechnology company developing innovative multispecific antibodies for oncology, announced that the company has entered into an exclusive worldwide licensing agreement for its OX40 antagonist monoclonal antibody portfolio with Astria Therapeutics, a biopharmaceutical company developing therapies for rare allergic and immunological diseases. With t...

Read More

Industrial Impact, Medical

SENSIBLE BIOTECHNOLOGIES ANNOUNCES PARTNERSHIP WITH GINKGO BIOWORKS TO DEVELOP NOVEL MRNA MANUFACTURING PLATFORM

prnewswire | April 04, 2023

news image

Sensible Biotechnologies, an early stage biotechnology company, today announced a partnership to develop an in vivo microbial mRNA manufacturing platform with Ginkgo Bioworks which is building the leading platform for cell programming and biosecurity. Today, the vast majority of mRNA used in vaccines, therapeutics and other applications is produced by in vitro transcription (IVT), a cell-free process, which is driven by purified enzymes. In conventional mRNA manufacturing, produ...

Read More

Medical

MERIDIAN BIOSCIENCE LAUNCHES LYO-READY™ QPCR INHIBITOR TOLERANT BLOOD-SPECIFIC MASTER MIXES FOR DNA & RNA DIRECT DETECTION

Meridian Bioscience, Inc. | March 31, 2022

news image

Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of two new master mixes that detect DNA and RNA in crude blood samples down to a single copy – enabling the earliest detection of cancer using non-invasive liquid biopsy. These two innovative mixes, Lyo-Ready™ Direct DNA qPCR Blood Mix and Lyo-Ready™ Direct RNA/DNA qPCR Blood Mix, are designed for applications that requir...

Read More

Cell and Gene Therapy

NEUROPHTH AND AAVNERGENE ANNOUNCES STRATEGIC AAV CAPSIDS PARTNERSHIP FOR NEXT-GENERATION OPHTHALMIC GENE THERAPY

Neurophth | January 19, 2021

news image

Neurophth Therapeutics, Inc., a subsidiary of Wuhan Neurophth Biotechnology Ltd. gene therapy organization, and AAVnerGene Inc., a practicing AAV innovation organization, reports a strategic partnership to provide Neurophth with overall rights to commonly choose adeno-associated virus (AAV) capsids for the next generation ophthalmic gene therapy. AAVnerGene's Tissue-specific, Highly-transductive and Expressive New AAVs (ATHENA) screening stage can productively choose the best ...

Read More
news image

Medical

ICHNOS SCIENCES ENTERS LICENSING AGREEMENT FOR OX40 ANTAGONIST MONOCLONAL ANTIBODY PORTFOLIO WITH ASTRIA THERAPEUTICS

PR Newswire | October 12, 2023

Ichnos Sciences, a global clinical-stage biotechnology company developing innovative multispecific antibodies for oncology, announced that the company has entered into an exclusive worldwide licensing agreement for its OX40 antagonist monoclonal antibody portfolio with Astria Therapeutics, a biopharmaceutical company developing therapies for rare allergic and immunological diseases. With t...

Read More
news image

Industrial Impact, Medical

SENSIBLE BIOTECHNOLOGIES ANNOUNCES PARTNERSHIP WITH GINKGO BIOWORKS TO DEVELOP NOVEL MRNA MANUFACTURING PLATFORM

prnewswire | April 04, 2023

Sensible Biotechnologies, an early stage biotechnology company, today announced a partnership to develop an in vivo microbial mRNA manufacturing platform with Ginkgo Bioworks which is building the leading platform for cell programming and biosecurity. Today, the vast majority of mRNA used in vaccines, therapeutics and other applications is produced by in vitro transcription (IVT), a cell-free process, which is driven by purified enzymes. In conventional mRNA manufacturing, produ...

Read More
news image

Medical

MERIDIAN BIOSCIENCE LAUNCHES LYO-READY™ QPCR INHIBITOR TOLERANT BLOOD-SPECIFIC MASTER MIXES FOR DNA & RNA DIRECT DETECTION

Meridian Bioscience, Inc. | March 31, 2022

Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of two new master mixes that detect DNA and RNA in crude blood samples down to a single copy – enabling the earliest detection of cancer using non-invasive liquid biopsy. These two innovative mixes, Lyo-Ready™ Direct DNA qPCR Blood Mix and Lyo-Ready™ Direct RNA/DNA qPCR Blood Mix, are designed for applications that requir...

Read More
news image

Cell and Gene Therapy

NEUROPHTH AND AAVNERGENE ANNOUNCES STRATEGIC AAV CAPSIDS PARTNERSHIP FOR NEXT-GENERATION OPHTHALMIC GENE THERAPY

Neurophth | January 19, 2021

Neurophth Therapeutics, Inc., a subsidiary of Wuhan Neurophth Biotechnology Ltd. gene therapy organization, and AAVnerGene Inc., a practicing AAV innovation organization, reports a strategic partnership to provide Neurophth with overall rights to commonly choose adeno-associated virus (AAV) capsids for the next generation ophthalmic gene therapy. AAVnerGene's Tissue-specific, Highly-transductive and Expressive New AAVs (ATHENA) screening stage can productively choose the best ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us